Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%

Methotrexate vs mycophenolate

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

Methotrexate probably leads to higher proportion of participants achieving steroid‐sparing control§… compared with mycophenolate (moderate certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 1.23 [1.01, 1.5]
2 studies · 261 participants
Moderate

Methotrexate vs mycophenolate

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

Methotrexate probably leads to higher proportion of participants achieving control of inflammation§… compared with mycophenolate (moderate certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 1.23 [1.01, 1.5]
2 studies · 261 participants
Moderate

Methotrexate vs mycophenolate

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found